You should read the following discussion and analysis in conjunction with the
Interim Financial Statements and the related notes thereto contained in Part I,
Item 1 of this Quarterly Report on Form 10-Q (this “Quarterly Report”). The
information contained in this Quarterly Report is not a…
Source: www.marketscreener.com – Read more
FDA approves breast cancer drug
The FDA has approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor positive, HER2-negative, ESR1-mutated advanced or
